KemPharm (NASDAQ:KMPH) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com reports. Zacks Investment Research currently has $1.00 target price on the specialty pharmaceutical company’s stock.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Other equities analysts also recently issued research reports about the company. ValuEngine upgraded KemPharm from a sell rating to a hold rating in a research report on Thursday, August 1st. Oppenheimer reduced their price objective on KemPharm from $8.00 to $3.00 and set an outperform rating on the stock in a research report on Thursday, May 23rd. Roth Capital cut KemPharm from a buy rating to a neutral rating and cut their target price for the stock from $4.25 to $1.05 in a research note on Thursday, September 5th. Finally, HC Wainwright reissued a buy rating and set a $3.00 target price on shares of KemPharm in a research note on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $2.01.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.09. Equities research analysts predict that KemPharm will post -1.15 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the business. RDA Financial Network acquired a new stake in KemPharm during the second quarter worth $28,000. Iowa State Bank increased its stake in KemPharm by 90.6% during the second quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock worth $77,000 after acquiring an additional 21,000 shares during the last quarter. BlackRock Inc. increased its stake in KemPharm by 21.7% during the second quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock worth $186,000 after acquiring an additional 19,001 shares during the last quarter. Geode Capital Management LLC increased its stake in KemPharm by 136.7% during the fourth quarter. Geode Capital Management LLC now owns 171,047 shares of the specialty pharmaceutical company’s stock worth $304,000 after acquiring an additional 98,775 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in KemPharm by 134.5% during the second quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock worth $2,341,000 after acquiring an additional 767,100 shares during the last quarter. 26.73% of the stock is owned by institutional investors.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Read More: What are Bollinger Bands?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.